Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00600) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
EP-101
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Drug in Phase 1 Clinical Trial
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=29243"></iframe>
|
 |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Inhibited by This Xenobiotics | ||||||
| Cytidine aminohydrolase (CDA) | DME Info | Homo sapiens | [1] | |||
| Xenobiotics-DME Activity Data | ||||||
| Xenobiotics-DME Activity Data | Cytidine aminohydrolase (CDA) | DME Info | IC50 = 0.113 microM | [1] | ||
| References | ||||||
| 1 | Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications. J Toxicol Sci. 2011 Aug;36(4):411-22. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.